November 9, 2026
Transgene Reports Continued Clinical Progress and Q3 2026 Financial Update
November 9, 2026
Third Quarter 2026 Financial Results
November 5, 2026
First Patient Dosed in Phase 1 Trial Evaluating Transgene’s and BioInvent’s BT-001 in Patients with Rectal Cancer
November 3, 2026
PoxSTG-EEV: a Novel Enveloped Virion – Based Formulation of a Chimeric Oncolytic PoxVirus Adapted for Systemic Delivery
November 3, 2026
Transgene to Present Preclinical Data on Novel Oncolytic Virus at SITC 2026 Supporting its Potential for Systemic Delivery
October 15, 2026
Synthetic genome shuffling of poxviruses in yeast generates novel poxvirus candidates with potential oncolytic properties
October 5, 2026
Transgene Will Present a Poster on Preclinical Data from a Novel Oncolytic Virus at SITC 2026
October 1, 2026
Transgene To Participate in Investor Access
September 24, 2026
Transgene Extends its myvac® Platform, Further Establishing its Position as a Key Player in the Rapidly Emerging Individualized Cancer Immunotherapy Field
September 24, 2026
Katell Bidet-Huang
September 24, 2026
Anne Stehlin
September 8, 2026
Transgene and ProBioGen Expand Strategic Partnership with Additional License Agreement for AGE1.CR.pIX Cell Line
September 2, 2026
Transgene and NEC Report 100% Three-Year Disease-Free Survival with TG4050 and Publish Phase 1 Results in Nature Communications
September 2, 2026
A viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: a randomized Phase I trial
June 29, 2026
Transgene expands myvac®into NSCLC with TG4070
June 25, 2026
Transgene to Present Preclinical Data Demonstrating Robust Protection Against Mpox with its Novel Scalable Cell Line-Derived MVA Vaccine Candidate (TG MVA(TM)) at WCID 2026
June 22, 2026
Transgene Expands myvac® into Non-Small Cell Lung Cancer with TG4070, an Individualized Neoantigen Therapeutic Vaccine
June 22, 2026
TG4070
June 19, 2026
Therapeutic Poxviruses Induce the Secretion of Immunostimulating and Anti-Tumoral Extracellular Vesicles
May 26, 2026
Robust Protection Against Monkeypox Virus Mediated by a Novel Cell‑Line–Derived MVA Vaccine (TG-MVACL)
May 26, 2026
Transgene to Present Preclinical Data on Novel TG-MVA Prophylactic Vaccine Against mpox at the World Congress on Infectious Diseases
May 22, 2026
Transgene’s Combined General Meeting of May 22, 2026
May 22, 2026
Solange Peters
May 22, 2026
Dorothea Ledergerber
May 4, 2026
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2026
April 29, 2026
Transgene Provides Business and Financial Update for Q1 2026
April 29, 2026
First Half 2026 Financial Results
April 26, 2026
Synthetic Genome Shuffling of Poxviruses via Yeast TAR Cloning for Next-Generation Oncolytic Platforms
April 13, 2026
Transgene Completes Patient Randomization in Phase 2 Part of Clinical Trial Evaluating TG4050 in the Adjuvant Treatment of Head and Neck Cancer
April 7, 2026
Transgene to Participate in Upcoming Investor Meetings
April 2, 2026
Transgene and NEC Bio Sign License Agreement to Prepare the Next Steps of the Development of TG4050 in Head and Neck Cancer
April 1, 2026
TG4050, an Individualized Neoantigen Therapeutic Vaccine in Early-Stage Cancer Treatment
March 26, 2026
Transgene to Deliver an Oral Presentation on its Individualized Neoantigen Therapeutic Vaccine TG4050 at the World Vaccine Congress
March 24, 2026
2025 Full-year results and business update
March 24, 2026
2025 Full-year Results
March 24, 2026
Transgene Continues Progress to Reshape Early-Stage Cancer Treatment through Individualized Neoantigen Therapeutic Vaccines (INTV) Backed by Financial Visibility Until Early 2028
March 24, 2026
Fériel MARIN
March 24, 2026
Sandrine LEMIUS
February 4, 2026
Transgene Announces Financial Calendar for 2026
January 23, 2026
Transgene Further Strengthens Scientific Advisory Board with Appointments of Renowned Cancer Immunotherapy Experts Antoine Italiano and Ignacio Melero
January 9, 2026
Transgene Publishes Phase I Data Supporting TG4050’s Potential in Preventing Head and Neck Cancer Relapse
January 9, 2026
Nature Communications
January 9, 2026
Viral-based individualized neoantigen vaccine as adjuvant treatment in resected head and neck squamous cell carcinoma: immunogenicity and efficacy from a randomized Phase I trial
January 6, 2026
search category
December 17, 2025
Transgene to Participate in Upcoming Investor Meetings
December 15, 2025
TG6050
December 11, 2025
teaser produits : tg6050
November 27, 2025
Transgene announces the resume of trading of its shares on Euronext Paris as of the opening of the markets
November 26, 2025
Transgene Announces the Success of Its Capital Increase
November 25, 2025
Announces the Temporary Suspension of Trading of its Shares on Euronext Paris
November 19, 2025
Colorectal Cancer Hepatic Metastasis Modeling by Advanced 3D Bioprinting Allows Demonstration of Oncolytic Viral Chemotherapeutic Delivery
November 14, 2025
TG4050 at 2025 SITC: New Ph.I immunological data
November 12, 2025
VacDesignR®: a Tool for Optimizing Recombinant Poxvirus Vaccine Production
November 7, 2025
Profiling of the neoantigen-specific T cell response after adjuvant TG4050 individualized therapeutic vaccination in a randomized phase I trial for locally advanced resected HPV-negative HNSCC
November 6, 2025
Transgene to Showcase Potential of Proprietary VacDesignR® Computational Tool to Optimize Individualized Therapeutic Cancer Vaccines
October 25, 2025
Contribution of yeast to synthetic virology
October 20, 2025
Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors
October 20, 2025
Updated clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb,administered in combination with pembrolizumab in patients with advanced solid tumors
October 19, 2025
Pooled Safety Analysis of Modified Vaccinia Virus Ankara-based Therapeutic Vaccine Alone or in Combination in Cancer and Cervical Intraepithelial Neoplasia (CIN) Clinical Trials
October 13, 2025
Transgene and BioInvent to Present Translational Data and Updated Clinical Results on Armed Oncolytic Virus BT-001, at ESMO 2025
October 3, 2025
Transgene to Present New Immunological Data from Phase I Trial of Individualized Therapeutic Cancer Vaccine, TG4050, at SITC 2025
September 24, 2025
TG6002 oncolytic vaccinia virusand chemotherapy synergy: apromising strategy for pancreaticductal adenocarcinoma
September 24, 2025
onglet presse releases
September 16, 2025
Transgene’s Individualized Neoantigen Therapeutic Cancer Vaccine TG4050 Delivers Positive Randomized Phase I Data – Randomization to be Completed in Phase II Part in Q4 2025
August 7, 2025
A Pseudocowpox virus vector to generate human B cell-based vaccines
July 27, 2025
Transgene and BioInvent to Present Updated Data on Armed Oncolytic virus BT-001 at ESMO 2025
July 23, 2025
Management committee
July 22, 2025
Sabine Tejpar
July 22, 2025
Ignacio Melero
July 22, 2025
Antoine Italiano
July 22, 2025
Fatima Cardoso
July 9, 2025
Transgene Appoints Seasoned Industry Executive Emmanuelle Quilès to Board of Directors as Independant Director
July 4, 2025
Utilisation de l’analyseur xCELLigence RTCA eSight pour l’évaluation de la nouvelle plateforme de virus oncolytique de Transgene
June 19, 2025
Transgene Completes Initial Patient Screening in Phase II Part of TG4050 Trial in Operable Head and Neck Cancer
June 13, 2025
Transgene to Participate in Upcoming Meetings with Biotech Industry Leaders
June 6, 2025
Listen to Prof. Ottensmeier explain the TG4050 Phase 1 data
June 3, 2025
Transgene to Host Webcast on Positive TG4050 Head and Neck Cancer Data Presented at ASCO 2025
June 1, 2025
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccin TG4050
June 1, 2025
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
May 26, 2025
teaser produits : Research & Innovation
May 22, 2025
Transgene to Present 24-month Disease-Free Survival Data from All Patients in Phase I Part of Trial of Individualized Cancer Vaccine, TG4050, at ASCO 2025
May 22, 2025
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
May 22, 2025
Randomized phase I trial of adjuvant personalized cancer vaccine TG4050 in resected locally advanced (LA) head and neck squamous cell carcinoma (HNSCC)patients (pts)
May 22, 2025
A randomized phase II trial evaluating the combination of TG4001, a HPV16 therapeutic vaccineand avelumab (ave) in patients (pts) with immunotherapy-naïve recurrent and/or metastatic(R/M) HPV16-positive cervical or anogenital cancer
May 15, 2025
Transgene’s Combined General Meeting of May 15, 2025
May 7, 2025
Credits
May 2, 2025
teaser tg-mva
May 2, 2025
teaser produits : placeholder
May 2, 2025
teaser produits: TG4070
April 24, 2025
Transgene Provides Business and Financial Update for Q1 2025
April 24, 2025
svg pipeline
April 24, 2025
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2025
April 23, 2025
Transgene to Provide Updated Phase I Data in a Rapid Oral Presentation on Individualized Therapeutic Cancer Vaccine TG4050 at ASCO 2025
April 15, 2025
A Phase I Clinical Trial of Intrahepatic Artery Delivery of TG6002 in Combination with Oral 5-Fluorocytosine in Patients with Liver-Dominant Metastatic Colorectal Cancer
April 10, 2025
Availability of Transgene’s 2024 Universal Registration Document (URD)
April 4, 2025
Our leadership
April 3, 2025
Simone STEINER
April 3, 2025
Corporate Governance
April 3, 2025
CG Governance and internal procedures
April 3, 2025
CG Management Committee
April 3, 2025
CG Board of Directors
April 1, 2025
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations
March 31, 2025
Financial reports 2026
March 27, 2025
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine – Strong Outlook for 2025
March 11, 2025
Transgene to Participate in Upcoming Investor Meetings
February 6, 2025
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts
January 21, 2025
Transgene To Participate in the Biomed Forum Investor Conference
January 14, 2025
Transgene Announces Financial Calendar for 2025
November 7, 2024
Transgene Reports Business, Pipeline and Financial Update for Q3 2024
November 7, 2024
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024
November 7, 2024
Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)
November 5, 2024
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Develpment
October 27, 2024
TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery
October 14, 2024
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers
October 7, 2024
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024
September 24, 2024
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025
September 24, 2024
Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity
September 14, 2024
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatment
September 14, 2024
Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors
September 10, 2024
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment
September 10, 2024
Emmanuelle DOCHY, MD
September 10, 2024
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation
September 10, 2024
Maurizio CEPPI, PhD
September 9, 2024
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024
September 5, 2024
Transgene to Participate in HTID Conference and Investor Access Forum in Paris
August 27, 2024
TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment
August 27, 2024
Transgene — Preclinical Proof of Concept Data of Oncolytic Virus TG6050 published in JITC
July 30, 2024
Transgene strengthens its balance sheet via equity conversion of current account advance from TSGH
July 22, 2024
Transgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024
June 3, 2024
Transgene – First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer
May 27, 2024
doublon Lucie Larguier
May 16, 2024
Michel Baguenault
May 15, 2024
Transgene’s Combined General Meeting of May 15, 2024
May 14, 2024
Transgene provides business and financial update for Q1 2024
April 24, 2024
Availability of of Preparatory Documents for the Combined General Meeting of May 15, 2024
April 11, 2024
Availability of Transgene’s 2023 Universal Registration Document
April 9, 2024
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
April 9, 2024
Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers
March 27, 2024
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
March 27, 2024
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
March 18, 2024
Transgene Announces Upcoming Investor Meetings
March 6, 2024
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
March 5, 2024
Transgene, Nec, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
January 22, 2024
Transgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer
January 22, 2024
Transgene Announces Financial Calendar for 2024
January 8, 2024
Transgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050
December 21, 2023
Transgene Announces Upcoming Investor Meetings
December 5, 2023
Transgene Strengthens its Leadership Team to Accelerate its Growth Strategy
November 7, 2023
Transgene reports business update and Q3 2023 financial position
October 10, 2023
Transgene and BioInvent – First patient treated in Part B of Phase I trial assessing the novel oncolytic virus BT-001 in combination with KEYTRUDA®(pembrolizumab)
September 20, 2023
Transgene advances its innovative immunotherapy pipeline and extends financial visibility until the end of 2024
September 14, 2023
Transgene Announces Upcoming Investor Meetings
August 29, 2023
Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
July 17, 2023
Transgene receives $15.3 Million from the Sale of Securities Held for Sale
June 6, 2023
Transgene and NEC Present New Data on TG4050, an Individualized Cancer Vaccine, Showing it Induces Specific Immune Responses against Head and Neck Carcinoma at ASCO 2023
June 5, 2023
Transgene presents immunological data demonstrating that TG4001, a novel therapeutic cancer vaccine, can induce T-cell responses against HPV16 antigens in the ongoing Phase II trial at ASCO 2023
May 26, 2023
Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma
May 26, 2023
Transgene to Present Data on its Two Therapeutic Cancer Vaccins at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
May 25, 2023
Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers
May 25, 2023
Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001 in solid tumors
May 10, 2023
Transgene provides business update and Q1 2023 financial position
May 10, 2023
Transgene – First Patient Dosed in Phase I Trial Evaluating TG6050, a Novel IL-12-Armed Oncolytic Virus Administrated Intravenously, in Non-Small Cell Lung Cancer
May 5, 2023
Transgene’s Combined General Meeting of May 5, 2023
May 5, 2023
Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio
April 19, 2023
PoxSTG, a novel chimeric poxvirus with improved oncolytic potency
April 19, 2023
Advanced patient-derived lung tumoroids to identify limiting factors for oncolytic virotherapy
April 18, 2023
New Data Showing that Transgene and NEC’s Individualized Cancer Vaccine TG4050 Induces Strong and Specific Immune Responses against Tumors Presented at AACR 2023
April 18, 2023
Feasibility and immunogenicity of adjuvant TG4050, a patient tailored cancer vaccine in head and neck and ovarian cancer
April 17, 2023
A randomized phase II trial of TG4001 plus avelumab versus avelumab alone in recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16 positive anogenital cancers
April 17, 2023
Oncolytic virus TG6002 safety and activity after intrahepatic artery administration in patients with liver-dominant metastatic colorectal cancer
April 17, 2023
Selection of an optimal anti-PD-L1 single domain antibody format for the vectorization into oncolytic vaccinia virus and the generation of bispecific immunomodulators
April 17, 2023
Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACR
April 16, 2023
Extracellular vesicles (EV): mediators of therapeutic vaccination? In vivo and in vitro characterization of EVs generated after infection of human and murine cells with therapeutic poxviruses
April 16, 2023
TG6050 an oncolytic vaccinia virus armed with interleukin 12 and anti-CTLA4 antibody induces TME remodeling and strong anti-tumoral responses
April 12, 2023
Transgene’s Board of Directors Proposes the Appointment of Carol Stuckley, MBA, as New Independent Director
April 11, 2023
Availability of Preparatory Documents for the Combined General Meeting of May 5, 2023
April 6, 2023
annonce kol event
April 6, 2023
Availability of Transgene’s 2022 Universal Registration Document
April 4, 2023
Transgene to Host KOL Webinar on TG4050: an Individualized Cancer Vaccine for the Treatment of HPV-Negative Head & Neck Cancers
March 27, 2023
Scientific advisors
March 27, 2023
Pedro Romero, MD
March 27, 2023
John C. Bell, PhD
March 27, 2023
Transgene Announces Upcoming Investor Meetings
March 16, 2023
Positive data on key clinical candidates delivered in 2022 – Promising outlook for 2023 as industry interest in therapeutic cancer vaccines and oncolytic viruses gains significant momentum
March 15, 2023
Transgene to Present Multiple Posters Highlighting the Potential of its Exciting Immunotherapy Pipeline at AACR 2023
March 9, 2023
Transgene Appoints John C. Bell and Pedro Romero as Key Scientific Advisors
January 6, 2023
Transgene Receives Approval to Start a Phase I Trial of TG6050, a Novel IL-12-Armed Oncolytic Virus Given by Intravenous Administration
January 4, 2023
Transgene announces Financial Calendar for 2023
December 15, 2022
Transgene Announces Upcoming Investor Meetings
November 14, 2022
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
November 7, 2022
Transgene reports business update and Q3 2022 financial position
November 2, 2022
Transgene Announces Positive Interim Analysis Results of Phase II Trial Evaluating TG4001 + Avelumab vs Avelumab in HPV-Positive Anogenital Cancers
September 27, 2022
R&D Day: Presentations to Highlight Transgene’s Competitive Positioning, Capabilities to Engineer Novel Immunotherapies for Patients with Cancer, and Update on Initial Clinical Data
September 18, 2022
annonceR&D
September 12, 2022
Transgene Confirms the Potential of the Intravenous Route of its Invir.IO™ Oncolytic Viruses against Solid Tumors with TG6002 Phase I Data Presented at ESMO Congress 2022
September 7, 2022
Positive Readouts for Transgene’s Clinical Stage Candidates Generated by its Two Innovative Platforms, with Further Clinical Data Expected in the Second Half of 2022
August 31, 2022
Transgene announces Upcoming Investor Meetings
June 28, 2022
Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
June 27, 2022
Transgene and BioInvent announce positive progress for BT-001
June 10, 2022
TG4050
June 10, 2022
annonce TG4050en
June 6, 2022
Advancing our pipeline
June 6, 2022
Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
June 6, 2022
Phase 1 studies of personalized neoantigen vaccine TG4050 in ovarian carcinoma (OC) and head and heck carcinoma (HNSCC)
May 27, 2022
Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
May 25, 2022
Carol Stuckley
May 25, 2022
Prof. Jean-Yves Blay
May 25, 2022
Dr. Alessandro Riva
May 25, 2022
Transgene’s Combined General Meeting of May 25, 2022
May 17, 2022
Transgene Announces Upcoming Investor Meetings
May 10, 2022
All of Transgene’s preclinical and clinical assets progressed in line with expectations in Q1 2022
May 8, 2022
Pseudocowpox virus, a novel vector to enhance the therapeutic efficacy of antitumor vaccination
April 17, 2022
Updated data of biodistribution and activity of oncolytic virus TG6002 after intravenous administrationin patients with advanced gastrointestinal carcinomas
April 12, 2022
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
April 11, 2022
Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
April 8, 2022
Transgene to Present New Positive Preliminary Phase I Clinical Data at AACR 2022, Reinforcing the Potential of TG4050
April 8, 2022
Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
April 7, 2022
Availability of Transgene’s 2021 Universal Registration Document
April 5, 2022
Availability of Preparatory Documents for the Combined General Meeting of May 25, 2022
March 31, 2022
Transgene’s Board of Directors strengthens its governance and proposes the appointment of Dr. Alessandro Riva as Independent Chairman
March 16, 2022
Transgene confirms the potential of its two innovative platforms and expects significant clinical results in 2022
March 9, 2022
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
March 9, 2022
Transgene to Present New Positive Preliminary Phase I Data on TG4050 (myvac® platform), its Individualized Therapeutic Cancer Vaccine, at AACR 2022
February 10, 2022
Transgene appoints Steven Bloom as Chief Business Officer
February 9, 2022
Ethics and compliance
January 20, 2022
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
January 18, 2022
Transgene and PersonGen Announce Collaboration to Evaluate a New Combination Therapy Against Solid Tumors
January 6, 2022
Transgene announces Financial Calendar for 2022
January 3, 2022
Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject « cold » tumors
December 15, 2021
Transgene announces License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Transgene’s Invir.IO™ Platform
November 22, 2021
Transgene and NEC announce positive preliminary data from Phase I studies of TG4050, a novel individualized neoantigen cancer vaccine
November 22, 2021
annonceHomeUS
November 14, 2021
annonce substitut
November 13, 2021
annonce
November 9, 2021
Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
November 4, 2021
Transgene reports business update and Q3 2021 financial position
October 1, 2021
Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
September 23, 2021
Publications
September 22, 2021
Transgene’s two innovative platforms progressing well – Financial visibility extended until end 2023
September 19, 2021
Sandrine Flory TSGH
September 19, 2021
Maya SAID
September 19, 2021
Alain MÉRIEUX
September 19, 2021
Marie LANDEL
September 19, 2021
Benoît HABERT
September 19, 2021
Jean-Luc BÉLINGARD
September 19, 2021
Emmanuelle QUILES
September 19, 2021
Christelle Schwoerer
September 19, 2021
John FELITTI
September 19, 2021
James Wentworth, PhD
September 19, 2021
Lucie Larguier
September 19, 2021
Christophe ANCEL
September 16, 2021
Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
September 16, 2021
Transgene presents data from Phase I clinical trial confirming the potential of the oncolytic virus TG6002
September 16, 2021
produits : BT-001
September 13, 2021
Transgene Announces Upcoming Investor Meetings
September 5, 2021
Annual General Meeting
September 5, 2021
événements et presentations
September 5, 2021
Analysts
September 5, 2021
General
September 5, 2021
Stock Information
September 5, 2021
Financial information
September 5, 2021
Key figures
September 5, 2021
Regulated information
September 3, 2021
teaserproduits : BT-001
September 1, 2021
Transgene Participates in New Cancer Research Consortium
August 29, 2021
FAQ patients
August 29, 2021
produits : TG4050
August 29, 2021
teaser produits : TG4050
August 26, 2021
pipeline
August 25, 2021
techno Oncolytic viruses
August 25, 2021
techno Therapeutic Vaccines
August 25, 2021
techno invirio
August 25, 2021
techno myvac
August 25, 2021
BoardDirectors
August 25, 2021
Management committee
August 25, 2021
Home news Container
July 1, 2021
3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
June 28, 2021
First Head & Neck Cancer Patient Enrolled in the UK in a Phase I Trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
June 24, 2021
First patient enrolled in expanded Phase II clinical trial of TG4001 + avelumab vs avelumab alone in patients with HPV16-positive anogenital cancers
June 22, 2021
Transgene announces the success of its Capital Increase via a Private Placement
June 21, 2021
Transgene Launches a Capital Increase via a Private Placement
June 8, 2021
Transgene Strengthens Global IP Protection for its Novel Invir.IO™ Oncolytic Viruses Encoding Immune Checkpoint Inhibitors (ICIs)
May 27, 2021
Transgene and BioInvent receive IND approval from the U.S. FDA for BT-001, a novel oncolytic virus for the treatment of solid tumors
May 26, 2021
Combined General Meeting of May 26, 2021
April 27, 2021
Transgene reports business update and end Q1 2021 financial position
April 12, 2021
Transgene Announces Upcoming Investor Meetings
April 9, 2021
Oncolytic virus TG6002 locates to tumors after intravenous infusion and induces tumor-specific expression of a functional pro-drug activating enzyme in patients with advanced gastrointestinal carcinomas
April 9, 2021
Transgene presents initial Phase I data of TG6002, highlighting the potential of the intravenous administration of its oncolytic viruses
April 7, 2021
Availability of Preparatory Documents for the Combined General Meeting of May 26, 2021
April 1, 2021
Availability of Transgene’s 2020 Universal Registration Document
March 30, 2021
Immunocompetent cancer-on-chip models to assess immuno-oncology therapy
March 10, 2021
Transgene expands Phase II clinical trial of therapeutic vaccine TG4001 in combination with avelumab versus avelumab monotherapy in patients with HPV16-positive anogenital cancers
March 10, 2021
Significant milestones achieved on all drug candidates in 2020 and financial visibility until 2022
March 2, 2021
Transgene to Present its Immuno-Oncology Expertise at Upcoming Scientific Conferences
March 1, 2021
Transgene and BioInvent have enrolled first patient in Phase I/IIa trial of novel oncolytic virus BT-001 in solid tumors
January 26, 2021
Safety, biodistribution and viral shedding of oncolytic vaccinia virus TG6002 administered intravenously in healthy beagle dogs
January 26, 2021
Correlation of HPV16 Gene Status and Gene Expression With Antibody Seropositivity and TIL Status in OPSCC
January 21, 2021
First Head & Neck Cancer Patient Treated in France in a Phase I trial with TG4050 (myvac® Platform), Transgene’s Innovative Individualized Immunotherapy
January 19, 2021
Transgene and BioInvent receive approval from ANSM to proceed with Phase I/IIa trial of anti-CTLA4-armed oncolytic virus BT-001 in solid tumors
January 14, 2021
Transgene Appoints Gaëlle Stadtler as Director of Human Resources
December 21, 2020
Transgene and BioInvent receive CTA approval for Phase 1/2a trial of oncolytic virus BT-001 in solid tumors
December 17, 2020
Transgene Announces Financial Calendar for 2021
December 16, 2020
Transgene Announces Investor Meetings for January 2021
December 3, 2020
Transgene to present Phase 1b/2 trial results of TG4001 in combination with avelumab in advanced HPV-positive cancers at ESMO IO 2020
December 3, 2020
Transgene appoints Hedi Ben Brahim as Chairman and Chief Executive Officer
November 26, 2020
Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
November 26, 2020
Fluorescent Tagged Vaccinia Virus Genome Allows Rapid and Efficient Measurement of Oncolytic Potential and Discovery of Oncolytic Modulators
November 9, 2020
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
November 9, 2020
TG4001 (Tipapkinogene sovacivec) and avelumab for recurrent/metastatic (R/M) Human Papilloma Virus (HPV)-16+ cancers: clinical efficacy and immunogenicity
November 9, 2020
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
November 9, 2020
Transgene and BioInvent present data on next generation oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
November 9, 2020
Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
November 5, 2020
Transgene reports business update and end Q3 2020 financial position
November 5, 2020
Transgene Presents its Individualized Immunotherapy, TG4050, at the Annual Neoantigen Based Therapies Summit
October 27, 2020
Transgene announces detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
October 19, 2020
Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on the detailed results from clinical study of TG4001 in combination with avelumab in advanced HPV-positive cancers
October 15, 2020
Transgene and BioInvent to present data on oncolytic virus BT-001 at the SITC 35th Anniversary Annual Meeting
October 6, 2020
Transgene, NEC and BostonGene Announce Strategic Collaboration for Two Ongoing Clinical Trials for Patients with Ovarian and Head & Neck Cancers
September 25, 2020
High Oncolytic Activity of a Double-Deleted Vaccinia Virus Copenhagen Strain against Malignant Pleural Mesothelioma
September 16, 2020
Positive clinical results for TG4001 and TG6002 and financial visibility secured until 2022
September 9, 2020
Transgene Announces Upcoming Investor Meetings
September 8, 2020
Positive initial data from a Phase 1 trial with Transgene’s oncolytic virus TG6002
September 2, 2020
Preclinical Evaluation of the Oncolytic Vaccinia Virus TG6002 by Translational Research on Canine Breast Cancer
August 25, 2020
Safety studies and viral shedding of intramuscular administration of oncolytic vaccinia virus TG6002 in healthy beagle dogs
August 4, 2020
Transgene Receives $22.2 million from the Sale of Part of its Minority Stake in Tasly BioPharmaceuticals
July 22, 2020
Transgene Reports Results from Clinical Study of TG4001 in Combination with Avelumab in Advanced HPV-Positive Cancers
July 9, 2020
Transgene and Hypertrust Patient Data Care announce successful go-live of the world’s first blockchain solution for clinical trials of personalized healthcare
July 8, 2020
Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
July 8, 2020
Design of an Innovative Model to Improve Anticancer Therapeutic Treatment Based on a Vascularized 3D Organoids Derived from Patients’ Lung Tumors for the Purpose of Precision Medicine
June 22, 2020
Oncolytic Vaccinia Virus expressing Cytidine Deaminase induces DNA damage and shows potent anti-tumor effects
June 22, 2020
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
June 22, 2020
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
June 22, 2020
Performance of neoantigen prediction for the design of TG4050, a patient specific neoantigen cancer vaccine
June 22, 2020
Transgene’s and BioInvent’s BT-001 achieves outstanding tumor cure rates in preclinical models
June 22, 2020
Transgene presents promising new data from its next-generation immunotherapy platforms at AACR 2020
May 27, 2020
Combined General Meeting of May 27, 2020
May 15, 2020
Transgene and BioInvent present preclinical data demonstrating BT-001’s powerful activity against solid tumors
May 15, 2020
Transgene and NEC demonstrate high accuracy of AI-based neoantigen prediction for the design of individualized cancer vaccine TG4050
May 6, 2020
Transgene reports Q1 2020 financial position and business update
May 4, 2020
Vaxxel acquires Transgene’s DuckCelt®-T17 cell line to develop industrial-scale vaccines against respiratory viruses
April 3, 2020
Availability of Transgene’s 2019 Universal Registration Document and update on the effect of Covid-19
April 3, 2020
Availability of Preparatory Documents for the Combined General Meeting of May 27, 2020
March 11, 2020
BT-001, an oncolytic Vaccinia virus armed with a Treg-depletion-optimized recombinant human anti- CTLA4 antibody and GM-CSF to target the tumor microenvironment
March 11, 2020
Major R&D milestones achieved in 2019 and strong clinical activity in 2020
March 3, 2020
Transgene and BioInvent to Present Data on BT-001, an Oncolytic Virus Encoding for an Anti-CTLA4 Antibody, at Upcoming Congresses
February 20, 2020
First Patient Dosed with Transgene’s Oncolytic Virus TG6002, Administered by Intrahepatic Artery Infusion in Colorectal Cancer with Liver Metastases
January 22, 2020
Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
January 7, 2020
Transgene and NEC Start Two Clinical Trials with TG4050, an individualized AI-Powered Cancer Vaccine for Ovarian and Head & Neck Cancers
December 18, 2019
Transgene Announces Financial Calendar for 2020
December 12, 2019
Transgene Reports on the Combination Trial of TG4010, Chemotherapy and Nivolumab in Non-Small Cell Lung Cancer
December 11, 2019
Transgene and BioInvent announce compelling preclinical data for BT-001 in solid tumors
December 9, 2019
Transgene Announces Investor Meetings for January 2020
November 17, 2019
Non-clinical and clinical safety of MVA-based immunotherapy products targeting cancer and infectious diseases
November 14, 2019
Transgene Provides Q3 2019 Business Update, with Focus on Recently Announced Efficacy Results of TG4001
November 8, 2019
Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
November 8, 2019
Meta analysis of two phase 1b randomized, double blind, placebo controlled clinical trials of the HBV therapeutic vaccines TG1050 and T101 developed in Europe/Canada or China
November 6, 2019
Oncolytic Vaccinia virus contains a potent CD80/CD86 ligand whose deletion confers higher tolerance, and potential synergy with immune arming
October 22, 2019
Transgene Will Participate in the Jefferies 2019 London Healthcare Conference
October 3, 2019
TG4001 + Avelumab Phase 1b results in HPV16+ R/M cancers
September 30, 2019
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
September 30, 2019
Transgene Reports First Promising Efficacy Results with TG4001 in Combination with Avelumab in HPV-Positive Cancer at ESMO 2019
September 30, 2019
Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers
September 27, 2019
Phase Ib/II trial of TG4001 (Tipapkinogene sovacivec), a therapeutic HPV-vaccine, and Avelumab in patients with recurrent/metastatic HPV16 positive cancers
September 18, 2019
Transgene Confirms the Timeline of its Clinical News Flow and Presents 2019 Half-Year Results
September 16, 2019
Transgene Receives Approval from the French Health Authority (ANSM) to Initiate Two Clinical Trials of its Lead myvac® Individualized Immunotherapy TG4050
August 29, 2019
Transgene Announces Upcoming Investor Meetings
August 7, 2019
Transgene Provides an Update after the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
August 2, 2019
Transgene Provides Update on PHOCUS Study of Pexa-Vec in Liver Cancer Following Planned Interim Futility Analysis
July 18, 2019
Transgene Receives MHRA Approval for a Clinical Trial of TG6002, a Next-generation Oncolytic Virus, Administered by Intrahepatic Artery Infusion in Patients with Colorectal Cancer with Liver Metastases
July 10, 2019
Transgene Receives MHRA Approval for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in HPV Negative Head and Neck Cancers in the UK
July 2, 2019
Success of Transgene’s €48.7 Million Rights Issue
June 14, 2019
Transgene Announces the Launch of a Rights Issue
June 5, 2019
Peer-reviewed publications confirm the potential of Transgene’s TG4001 and TG6002
May 27, 2019
Last Patient Enrolled in the Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Advanced Lung Cancer (NSCLC)
May 22, 2019
Combined General Meeting of May 22, 2019
May 13, 2019
Financial visibility extended to Q4 2020, including $10 million revenue from collaboration with AstraZeneca to be received in Q2 2019
May 13, 2019
Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
May 9, 2019
Transgene Announces Upcoming Investor Meetings
May 9, 2019
Availability of Preparatory Documents for the Combined General Meeting of May 22, 2019
May 2, 2019
Transgene and AstraZeneca enter into a collaboration and exclusive license option agreement for innovative Invir.IO(TM) based armed oncolytic immunotherapies
April 18, 2019
The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
April 18, 2019
The efficacy and safety of Tipapkinogen Sovacivec (TG4001) therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3: Randomized controlled phase II trial with 2.5 years of follow-up
March 27, 2019
The Enhanced Tumor Specificity of TG6002, an Armed Oncolytic Vaccinia Virus Deleted in Two Genes Involved in Nucleotide Metabolism
March 26, 2019
Transgene and BioInvent Extend their Collaboration to Develop Multifunctional Oncolytic Viruses for the Treatment of Solid Tumors
March 20, 2019
Transgene: A positive 2018, moving ahead with a strong portfolio
March 18, 2019
Transgene secures a €20 Million Revolving Credit Facility with Natixis
March 13, 2019
NEOVIVA project supporting the development of myvac® awarded a €5.2 million grant from Bpifrance’s “Investments for the Future” programme
March 7, 2019
2018 Half-Year Results and Business Update
March 5, 2019
Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
December 20, 2018
Transgene Completes Safety and Tolerability Assessment of TG4001 in Combination with Avelumab in Phase 1b Part of Trial in HPV-Positive Cancer Patients
December 17, 2018
Transgene Announces Financial Calendar for 2019
December 5, 2018
Transgene Announces Upcoming Investor Meetings
November 30, 2018
Investigational treatment combining TG1050, an HBV-specific immunotherapeutic, with direct acting antivirals or immunomodulators, improves sustained antiviral effects and immune responses in HBV-persistent mice
November 12, 2018
Transgene – Positive Results from Phase 1 Clinical Trial of TG1050 in Chronic Hepatitis B Presented at the AASLD Liver Meeting 2018
November 7, 2018
Antibody-armed oncolytic Vaccinia virus to block immunosuppressive pathways in the tumor microenvironment
November 7, 2018
Safety and Immunogenicity of Single and Multiple Injections of the Therapeutic Vaccine TG1050 in NUC-Suppressed Chronic Hepatitis B (CHB) Patients: Unblinded Analysis of a Double-Blind, Placebo-Controlled Phase 1b Study
November 7, 2018
myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
November 7, 2018
Pseudocowpox virus (PCPV), a potent viral vector for both antigen-dependent and independent cancer immunotherapy
November 7, 2018
Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
November 7, 2018
Transgene and BioInvent present positive data at the SITC, supporting the co-development of a next-generation oncolytic virus encoding for an anti-CTLA-4 antibody
October 30, 2018
NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
October 25, 2018
€26.6 million in cash and cash equivalents as of September 30, 2018
October 17, 2018
First Patient Dosed in a Phase 1/2 Trial of Transgene’s Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors
October 10, 2018
Transgene to Present Positive Results from Phase 1b Trial of TG1050 in Patients with Chronic Hepatitis B at Upcoming AASLD Liver Meeting 2018
October 2, 2018
Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
September 24, 2018
Transgene unveils myvac™, an individualized immunotherapy against solid tumors
September 19, 2018
Transgene Presents 2018 Half-Year Results and Business Update
September 3, 2018
Transgene Announces Upcoming Investor Meetings
August 20, 2018
Transgene completes the sale of the Greater China rights of TG6002 and TG1050 to Tasly Biopharmaceuticals for $48 million in newly-issued shares
July 10, 2018
Transgene and Tasly Biopharmaceuticals conclude strategic agreements for the rights of TG6002 and TG1050 in Greater China
June 4, 2018
Transgene’s Lead Oncolytic Virus Pexa-Vec Triggers Strong Anti-Tumor Immunity after Intravenous Administration
May 24, 2018
Transgene Announces Upcoming Investor Meetings
May 23, 2018
Combined General Meeting of May 23, 2018
May 17, 2018
Single intravenous preoperative administration of the oncolytic virus Pexa-Vec to prime anti-tumor immunity
May 17, 2018
Transgene to Present New Clinical Data on Oncolytic Virus Pexa-Vec at ASCO 2018
May 2, 2018
A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis
May 2, 2018
Availability of Preparatory Documents for the Combined General Meeting (Ordinary and Extraordinary Sessions) of May 23, 2018
April 26, 2018
€35.6 Million in Cash and Cash Equivalents as of March 31, 2018
April 18, 2018
Pseudocowpox: A next generation viral vector for cancer immunotherapy
April 18, 2018
Transgene Presents Data on a Novel Viral Vector with Remarkable Anticancer Activity at AACR 2018
April 17, 2018
TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
April 9, 2018
H. C. Wainwright Global Life Sciences Conference: April 9, 2018 – Monte Carlo, Monaco
March 21, 2018
Transgene to announce major clinical results in 2018 and achieve promising progress on its new oncolytic viruses
March 15, 2018
Transgene to Present Data on a Novel Viral Vector with Superior Anti-Cancer Immunotherapeutic Activity at AACR 2018
January 17, 2018
First Chronic Hepatitis B Patient Dosed in China in a Phase 1 Trial of T101 (Transgene’s TG1050 Technology)
January 16, 2018
First Patient Dosed in a Phase 2 Trial with Transgene’s TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)
December 21, 2017
Transgene Announces Financial Calendar for 2018
December 18, 2017
Transgene Announces Upcoming Investor Meetings
December 6, 2017
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
November 10, 2017
Transgene successfully raises € 14.4 million from U.S. and European investors
November 9, 2017
Transgene launches a capital increase by way of an accelerated book build offering
October 30, 2017
Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017
October 26, 2017
First Patient Treated in a Phase 1/2a Trial (Oncovirac) of Novel Oncolytic Virus TG6002 in Recurrent Glioblastoma
October 23, 2017
TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
October 23, 2017
TG1050 is well tolerated and induces a strong specific immune response in patients with chronic hepatitis B
October 19, 2017
Third Quarter Marked by Progress in Clinical Development and Research
October 17, 2017
Transgene Presents First Clinical Data Indicating that TG1050 Induces a Robust and HBV-Specific Cell-Mediated Immune Response in Patients with Chronic Hepatitis B
October 12, 2017
Viral based vaccine TG4010 induces broadening of specific immune response and improves outcome in advanced NSCLC
October 12, 2017
Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
October 12, 2017
Peer Reviewed Scientific Publications Highlight TG4010’s Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors
October 2, 2017
Transgene and Randox Sign Collaboration to Develop Innovative Multifunctional Oncolytic Virotherapies for Solid Tumors
September 21, 2017
Transgene Launches Invir.IO™, its Integrated Platform for the Next Generation of Multifunctional Oncolytic Viruses
September 19, 2017
First Patient Treated in a Phase 1b/2 Trial of TG4001 in Combination with Avelumab in HPV-Positive Cancers
September 13, 2017
First half-year 2017 in line with our objectives: All clinical programs progressing and new collaboration agreements signed
September 11, 2017
Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer (NSCLC)
September 7, 2017
Transgene and Institut Bergonié Present a Poster on the METROmaJX Trial (Oncolytic Virus Pexa-Vec + Metronomic Cyclophosphamide) at ESMO 2017 Congress
September 7, 2017
A phase Ib trial of JX-594 (Pexa-Vec), a targeted multimechanistic oncolytic vaccinia virus, in combination with low-dose cyclophosphamide in patients with advanced solid tumors
August 31, 2017
Transgene Announces Upcoming Investor Meetings
August 26, 2017
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
July 31, 2017
First Patient Dosed in a Phase 1/2 Trial of Pexa-Vec + Opdivo® for the First-Line Treatment of Advanced Liver Cancer
July 24, 2017
Immune Checkpoint Blockade, Immunogenic Chemotherapy or IFN-α Blockade Boost the Local and Abscopal Effects of Oncolytic Virotherapy
July 24, 2017
Transgene Announces Cancer Research Publication Confirming the Potential of its Next Generation Armed Engineered Oncolytic Virus
June 29, 2017
Servier and Transgene have become partners to apply viral vectorization technology to the engineering of allogenic CAR-T.
June 22, 2017
Transgene Hosts Immuno-Oncology R&D Day Focused on Modulating the Tumor Micro-Environment in Paris
June 8, 2017
Combined General Meeting of June 8, 2017
June 5, 2017
TG6002: A novel oncolytic and vectorized gene pro-drug therapy approach to treat glioblastoma
April 25, 2017
€50.7 Million in Cash and Cash Equivalents as of March 31, 2017
April 25, 2017
Transgene and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate TG4010 in Combination with Opdivo and Standard Chemotherapy in First Line Non-Small Cell Lung Cancer
April 24, 2017
SillaJen and Transgene Announce the Enrollment of the First European Patient in Multinational Phase 3 Trial for Pexa-Vec in Advanced Liver Cancer
April 19, 2017
Kempen 10th Life Sciences Conference: April 19, 2017 – Amsterdam, Netherlands
April 19, 2017
Marie Landel and Maya Said Nominated to be Independent Members of Transgene’s Board of Directors
April 12, 2017
Transgene and Institut Bergonié Start the Phase 2 Part of the METROmaJX Trial
April 10, 2017
Transgene Announces Upcoming Investor Meetings and R&D Day
April 5, 2017
Local and Abscopal Effects in Oncolytic Virotherapy are boosted by Immune Checkpoint Blockade, Immunogenic Chemotherapy, or IFNAR blockade
April 2, 2017
In situ Biomarker analysis in cancer Immunotherapy: development of quantitative multiplex IHC
March 30, 2017
Transgene Presents Very Promising New Immunology Data of its Next Generation Armed Oncolytic Virus at the AACR Annual Meeting in Washington, DC
March 20, 2017
Major achievements in 2016 validate Transgene’s strategy and provide promising outlook for 2017
March 13, 2017
First Patient dosed in Phase 2 Trial Evaluating Transgene’s TG4010 in Combination with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
February 22, 2017
Vectorized gene therapy of liver tumors: proof-of-concept of TG4023 (MVA-FCU1) in combination with flucytosine
February 13, 2017
Transgene and Léon Bérard Cancer Center Announce Dosing of the First Patient in a Phase 1 Immunotherapy Clinical Trial Evaluating the Intra-Tumoral Co-Administration of Pexa-Vec plus Ipilimumab (Yervoy®) in Solid Cancers
January 20, 2017
Radiotherapy and MVA-MUC1-IL-2 vaccine act synergistically for inducing specific immunity to MUC-1 tumor antigen
January 5, 2017
Transgene Announces Financial Calendar for 2017
December 22, 2016
Transgene Announces Upcoming Investor Events
December 7, 2016
UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo® (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) / The trial will be supported by Transgene and Bristol-Myers Squibb
November 14, 2016
TG1050, an HBV-targeted immunotherapeutics, efficiently decreases HBV viremia and antigenemia in a preclinical model; a meta-analysis and the determination of the involvement of CD4 and CD8 T cells.
November 14, 2016
Transgene presents preclinical results of TG1050, an HBV-targeted immunotherapy, at AASLD 2016 Liver Meeting
November 10, 2016
Successful Completion of Transgene’s Rights Issue – Gross proceeds of circa €46.4 million
October 28, 2016
Transgene Announces Publication in OncoImmunology of Pre-Clinical Data Demonstrating Delivery of a Fully Functional Immune Checkpoint Inhibitor (ICI) with Anti-Tumor Efficacy by a New Generation of Oncolytic Viral Immunotherapy
October 28, 2016
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
October 20, 2016
Transgene Reports Third Quarter 2016 Financial Results
October 20, 2016
Transgene Announces Rights Issue
October 18, 2016
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
October 17, 2016
First Patient Randomized in Multiple Dose Cohort of Phase 1/1b Trial with Transgene’s TG1050 in Chronic Hepatitis B Patients
October 11, 2016
Transgene Announces Collaboration with Merck and Pfizer to Evaluate the Combination of TG4001 with Avelumab in HPV-Positive Head & Neck Cancer in a Phase 1/2 Study
October 5, 2016
Engineering Oncolytic Vaccinia Virus with Improved Cancer Killing Abilities
October 5, 2016
Transgene presents data on improved cytotoxic activity of oncolytic viruses expressing intrabodies in resistant tumor cell lines
September 5, 2016
Transgene Provides an Update on its Development Strategy and on its First Half-Year 2016 Financials
September 1, 2016
Transgene Announces Participation at Upcoming Investor Events
July 21, 2016
Transgene to Continue Phase 1/1b Study with TG1050 in Chronic Hepatitis B Patients on the Recommendation of the Trial’s Safety Review Committee
July 1, 2016
Evaluation of a novel oncolytic Raccoonpox virus expressing the bifunctional FCU1 suicide gene
July 1, 2016
Improvement of MVA-based Vaccines by Expression of an Autophagy Inhibitor
July 1, 2016
Oncolytic vaccinia virus TG6002 demonstrates potent efficiency in pancreatic tumor alone and in combination with standard chemotherapies
June 6, 2016
A Phase 3 Randomized, Open-Label Study Comparing Pexa-Vec (Vaccinia GM-CSF / Thymidine Kinase-Deactivated Virus) Followed by Sorafenib Versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC) Without Prior Systemic Therapy
May 31, 2016
Transgene Announces Poster Presentation at ASCO Annual Meeting on the Phase 3 PHOCUS Clinical Trial with Pexa-Vec Oncolytic Immunotherapy
May 25, 2016
Composition of the Board of Directors and Statutory Auditors
April 26, 2016
Next Annual General Meeting on 24 May 2016
April 21, 2016
Transgene Reports First Quarter 2016 Business Update
April 19, 2016
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death-1 (PD-1) allow their intratumoral delivery and an improved tumor growth inhibition
April 19, 2016
Vectorization in an oncolytic vaccinia virus of an antibody, a Fab and a scFv against programmed cell death -1 (PD-1) allow their intratumoral delivery and an improved tumor-growth inhibition
April 19, 2016
Transgene Presents Pre-Clinical Data at AACR on a New Generation Oncolytic Viral Immunotherapy Armed with an Anti-PD1 Monoclonal Antibody (poster)
April 7, 2016
9th Kempen & Co Healthcare & Life Sciences Conference – Amsterdam
March 17, 2016
Transgene Hires Two Senior Pharmaceutical Industry Executives to Join Leadership Team
March 8, 2016
Transgene Reports 2015 Financial Results and Provides Outlook for 2016 (webcast)
March 2, 2016
Transgene Announces Participation at Upcoming Investor Events
February 3, 2016
Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset
January 28, 2016
EIB lends EUR 20m to Transgene
January 8, 2016
Transgene Announces Financial Calendar for 2016
January 7, 2016
Transgene enters new phase in its strategic development
January 6, 2016
Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
December 23, 2015
Transgene Announces Publication in “The Lancet Oncology” of Phase 2b TIME Trial Results with TG4010 Immunotherapy in Non-Small Cell Lung Cancer
December 18, 2015
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial
November 24, 2015
A Novel MVA-Based Multiphasic Vaccine for Prevention or Treatment of Tuberculosis Induces Broad and Multifunctional Cell-Mediated Immunity in Mice and Primates
November 13, 2015
TG4010 immunotherapy plus chemotherapy as first-line treatment of advanced NSCLC: Phase 2b Results of the TIME trial
November 12, 2015
Transgene and SillaJen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development
November 4, 2015
Transgene Announces Dosing of First Patient with TG1050 for Treatment of Chronic Hepatitis B Infection
October 21, 2015
Transgene Reports Third Quarter 2015 Financial Results
September 23, 2015
Transgene to Present at Ladenburg Thalmann 2015 Healthcare Conference in New York
September 18, 2015
Recognition of core-derived epitopes from a novel HBV-targeted immunotherapeutic by T-cells from patients infected by different viral genotypes.
September 10, 2015
Transgene Reports Financial Results for First Six Months of 2015 (interim report)
September 10, 2015
TG4010 Immunotherapy plus Chemotherapy as First Line Treatment of Advanced NSCLC: Phase 2b Results.
September 8, 2015
Transgene Announces Final Overall Survival Data from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer Presented at World Conference on Lung Cancer
August 19, 2015
Transgene Announces Oral Presentation on TG4010 Cancer Immunotherapy at World Conference on Lung Cancer
June 29, 2015
Transgene plans restructuring to focus on research and development
June 1, 2015
Transgene Announces Positive New Results Presented at ASCO from Phase 2b TIME Trial with TG4010 Immunotherapy in Non-Small Cell Lung Cancer (poster)
June 1, 2015
Results of the Phase 2B Part of Time Study Evaluating TG4010 Immunotherapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients Receiving First-Line Chemotherapy
May 18, 2015
Transgene Announces Participation at Upcoming Investor Events
April 30, 2015
TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
April 30, 2015
TG1050, a Novel Immunotherapeutic to Treat Chronic Hepatitis B, can Control HBsAg and Provoke HBsAg Seroconversion in HBV-Persistent Mouse Models
April 28, 2015
Interview with Philippe Archinard on TV Finance
April 23, 2015
Transgene Presents New Data with TG1050, an Immunotherapy being Developed to Treat Chronic Hepatitis B, at The International Liver Congress™ 2015
April 22, 2015
Transgene Reports First Quarter 2015 Financial Results
April 21, 2015
Transgene Presents New Pre-Clinical Data at AACR on (i) the Combination of TG4010 with Immune Checkpoint Inhibitors; (ii) TG3003, an Anti-CD115 Monoclonal Antibody
April 21, 2015
Immune checkpoint inhibitors enhance benefits of modified vaccinia virus Ankara to improve survival in preclinical models of cancer
April 21, 2015
The MVA viral platform for the treatment of cancer and chronic infectious diseases: Clinical experience from four randomized controlled phase II studies
April 16, 2015
Agreement with FDA Announced for Special Protocol Assessment for Upcoming Phase 3 Pexa-Vec Trial in Advanced Liver Cancer
March 24, 2015
Transgene Reports 2014 Financial Results and Outlines Promising Clinical Pipeline (webcast)
March 19, 2015
Transgene Announces New Pre-Clinical Data with TG4010 in Combination with Immune Checkpoint Inhibitors and TG3003 (humanized mAb anti-CD115) to be Presented at AACR
February 5, 2015
Viral hepatitis: HBV cure—can we pin our hopes on immunotherapy ?
January 8, 2015
Transgene Announces Financial Calendar for 2015
December 1, 2014
Corporate presentation
November 26, 2014
TG1050, an immunotherapeutic to treat chronic hepatitis B, induces robust T cells and exerts an antiviral effect in HBV-persistent mice.
November 6, 2014
TG4010 Immunotherapy Combined with First-line Therapy in Advanced Non- Small Cell Lung Cancer (NSCLC). Phase 2b Results of the TIME Study
October 21, 2014
Transgene Announces Third Quarter 2014 Financial Results
September 30, 2014
TIME: A Phase 2b/3 Evaluating TG4010 in Combination with First-line Therapy in Advanced Non-Small Cell Lung Cancer (NSCLC). Phase 2b results.
September 8, 2014
Transgene Reports Financial Results for First Six Months of 2014 and Provides Update on TG4010
July 1, 2014
Efficacy of immunotherapy with TG4040, Peg-interferon, and ribavirin in A phase 2 study of patients with chronic HCV infection.
June 17, 2014
June 17, 2014 – Letter to shareholders
May 30, 2014
Comparative analysis of immunization schedules using a novel adenovirus – based immunotherapeutic targeting hepatitis B in naïve and tolerant mouse models.
April 22, 2014
Transgene Reports First Quarter 2014 Financial Results
March 26, 2014
Transgene Reports Fiscal Year 2013 Results and Provides Business Update
January 31, 2014
Immunotherapy for non – small – cell lung cancer: current approaches.
October 15, 2013
TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.
October 15, 2013
TG1050, A viral-vector based immunotherapeutic designed to treat chronic hepatitis B induces immune responses similar to those display by HBV resolving patients and has an early antiviral effects in a HBV tolerant model.
September 3, 2013
Pre-clinical proof-of-concept studies exploring schedules of administration of an adenovirus-based HBV immunotherapeutic show wide potential for induction of robust and long-lasting T-cell responses.
September 3, 2013
130 – A multivalent adenovirus-based immunotherapeutic for treatment of chronic hepatitis B induces broad, robust and polyfunctional T cells in naive and HBV tolerant mice.
May 20, 2013
Phase II trial of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, followed by sorafenib in patients with advanced hepatocellular carcinoma (HCC)
May 20, 2013
Phase Ib dose-escalation study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia virus, administered by intravenous (IV) infusions in patients with metastatic colorectal carcinoma (mCRC)
May 15, 2013
Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans
March 19, 2013
Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
March 12, 2013
Therapeutic cancer vaccines in the treatment of non-small cell lung cancer